ONC vs. NVO

Last updated Apr 2, 2026

Compare and contrast key facts about BeOne Medicines Ltd (ONC) and Novo Nordisk A/S (NVO).

Performance

ONC vs. NVO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in BeOne Medicines Ltd (ONC) and Novo Nordisk A/S (NVO). The values are adjusted to include any dividend payments, if applicable.

ONC vs. NVO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
ONC BeOne Medicines Ltd	1.52%	64.48%	2.41%	-18.00%	-18.82%	4.85%	55.88%	18.18%	43.53%	221.87%
NVO Novo Nordisk A/S	-25.80%	-39.22%	-15.93%	54.84%	22.66%	63.52%	23.33%	28.70%	-12.98%	52.92%

Fundamentals

Market Cap ONC : $34.99B NVO : $162.26B
EPS ONC : $2.53 NVO : $22.15
PE Ratio ONC : 122.12 NVO : 1.65
PS Ratio ONC : 6.56 NVO : 0.55
PB Ratio ONC : 8.02 NVO : 0.84
Total Revenue (TTM) ONC : $5.34B NVO : $297.20B
Gross Profit (TTM) ONC : $4.67B NVO : $240.66B
EBITDA (TTM) ONC : $515.55M NVO : $153.18B

Returns By Period

In the year-to-date period, ONC achieves a 1.52% return, which is significantly higher than NVO's -25.80% return. Over the past 10 years, ONC has outperformed NVO with an annualized return of 26.58%, while NVO has yielded a comparatively lower 5.04% annualized return.

ONC

• 1D: 3.86%
• 1M: -1.88%
• YTD: 1.52%
• 6M: -7.97%
• 1Y: 13.80%
• 3Y*: 12.69%
• 5Y*: -2.06%
• 10Y*: 26.58%

NVO

• 1D: -0.73%
• 1M: -0.01%
• YTD: -25.80%
• 6M: -36.19%
• 1Y: -43.88%
• 3Y*: -20.88%
• 5Y*: 3.69%
• 10Y*: 5.04%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ONC vs. NVO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ONC

ONC Risk / Return Rank: 50
ONC Sharpe Ratio Rank: 51
ONC Sortino Ratio Rank: 48
ONC Omega Ratio Rank: 46
ONC Calmar Ratio Rank: 52
ONC Martin Ratio Rank: 52

NVO

NVO Risk / Return Rank: 10
NVO Sharpe Ratio Rank: 8
NVO Sortino Ratio Rank: 11
NVO Omega Ratio Rank: 10
NVO Calmar Ratio Rank: 11
NVO Martin Ratio Rank: 11

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ONC vs. NVO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for BeOne Medicines Ltd (ONC) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ONC	NVO	Difference
Sharpe ratio Return per unit of total volatility	0.30	-0.81	+1.11
Sortino ratio Return per unit of downside risk	0.76	-0.99	+1.76
Omega ratio Gain probability vs. loss probability	1.09	0.86	+0.23
Calmar ratio Return relative to maximum drawdown	0.49	-0.82	+1.31
Martin ratio Return relative to average drawdown	1.11	-1.41	+2.53
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ONC vs. NVO - Sharpe Ratio Comparison

The current ONC Sharpe Ratio is 0.30, which is higher than the NVO Sharpe Ratio of -0.81. The chart below compares the historical Sharpe Ratios of ONC and NVO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	ONC	NVO	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.30	-0.81	+1.11
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.04	0.10	-0.13
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.48	0.16	+0.32
Sharpe Ratio (All Time) Calculated using the full available price history	0.47	0.46	+0.01

Correlation

The correlation between ONC and NVO is 0.21, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ONC vs. NVO - Dividend Comparison

ONC has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 4.94%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
ONC BeOne Medicines Ltd	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NVO Novo Nordisk A/S	4.94%	3.31%	1.68%	1.00%	1.20%	1.35%	1.87%	2.14%	1.45%	1.52%	2.87%	0.92%

Drawdowns

ONC vs. NVO - Drawdown Comparison

The maximum ONC drawdown since its inception was -69.96%, smaller than the maximum NVO drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for ONC and NVO.

Drawdown Indicators

	ONC	NVO	Difference
Max Drawdown Largest peak-to-trough decline	-69.96%	-74.70%	+4.74%
Max Drawdown (1Y) Largest decline over 1 year	-27.22%	-55.03%	+27.81%
Max Drawdown (5Y) Largest decline over 5 years	-69.96%	-74.70%	+4.74%
Max Drawdown (10Y) Largest decline over 10 years	-69.96%	-74.70%	+4.74%
Current Drawdown Current decline from peak	-23.49%	-73.49%	+50.00%
Average Drawdown Average peak-to-trough decline	-29.71%	-17.56%	-12.15%
Ulcer Index Depth and duration of drawdowns from previous peaks	11.96%	31.83%	-19.87%

Volatility

ONC vs. NVO - Volatility Comparison

BeOne Medicines Ltd (ONC) has a higher volatility of 10.56% compared to Novo Nordisk A/S (NVO) at 9.39%. This indicates that ONC's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ONC	NVO	Difference
Volatility (1M) Calculated over the trailing 1-month period	10.56%	9.39%	+1.17%
Volatility (6M) Calculated over the trailing 6-month period	27.94%	38.79%	-10.85%
Volatility (1Y) Calculated over the trailing 1-year period	46.66%	54.16%	-7.50%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	56.67%	37.82%	+18.85%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	55.89%	32.28%	+23.61%

Financials

ONC vs. NVO - Profitability Comparison

The chart below illustrates the profitability comparison between BeOne Medicines Ltd and Novo Nordisk A/S over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

ONC - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, BeOne Medicines Ltd reported a gross profit of 1.36B and revenue of 1.50B. Therefore, the gross margin over that period was 90.5%.

NVO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Novo Nordisk A/S reported a gross profit of 54.38B and revenue of 67.28B. Therefore, the gross margin over that period was 80.8%.

ONC - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, BeOne Medicines Ltd reported an operating income of 185.04M and revenue of 1.50B, resulting in an operating margin of 12.4%.

NVO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Novo Nordisk A/S reported an operating income of 27.12B and revenue of 67.28B, resulting in an operating margin of 40.3%.

ONC - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, BeOne Medicines Ltd reported a net income of 66.50M and revenue of 1.50B, resulting in a net margin of 4.4%.

NVO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Novo Nordisk A/S reported a net income of 22.96B and revenue of 67.28B, resulting in a net margin of 34.1%.